Schonfeld Strategic Advisors’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-42,300	Closed	-$858K	–	2949
2022 Q4	$858K	Buy	+42,300	New	+$648K	0.01%	1233

Schonfeld Strategic Advisors's OPNT Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 42,300 shares — an estimated $858K sold.

Schonfeld Strategic Advisors first reported a position in OPNT in Q4 2022 and held it in 1 quarter. The position peaked at $858K in Q4 2022. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

Schonfeld Strategic Advisors reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 42,300 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $858K.
Schonfeld Strategic Advisors first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
Schonfeld Strategic Advisors's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $858K in Q4 2022.
0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.